best digital health platforms with glp-1 coverage options What's next for innovation: A primer on the race reshaping pharma and chronic disease care Ro launches GLP-1 insurance coverage

GLP-1 agonists can reduce thirst signals alongside appetite signals

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: A randomised, placebo-controlled and active comparator-controlled phase 2 trial

None of that is a criticism of the study its the homework that comes next.

28,29 Although highly effective, 30 patients must administer injections of exenatide multiple times a day leading to low patient compliance

This proved it to have fewer severe side effects in clinical trials and to cause less weight gain than other existing diabetics drugs

Direct head-to-head data does not yet exist, so any Retatrutide is better than Mounjaro/Wegovy claim should be treated as provisional until such trials are conducted